Cure SMA and the SMA Community Featured by Astellas Pharmaceuticals
Cure SMA is featured by Astellas Pharmaceuticals as part of their new Changing Tomorrow Together website. Cure SMA Research Director Jill Jarecki contributed a spotlight piece about Cure SMA’s research model: how and why we fund different areas of research, and the crucial role our community plays in drug development for SMA.
Because of the dedication and persistence of our community, and the ongoing work of our research and clinical partners, SMA drug development has become a model that many in the rare disease community seek to emulate.
In participating in projects like Changing Tomorrow Together, the Global Genes Rare Toolkits, TRAIN and Partnering for Cures, our goal is both to learn from our partners, and to share our expertise with them wherever we can. We believe that collaboration is one of the key ways we can make progress toward our goal of a treatment and cure for SMA.
About the Changing Tomorrow Together Project
Changing Tomorrow Together, an online resource managed by the Astellas Stakeholder Engagement team, was created to stimulate dialogue and create opportunities to share information, inspiration and ideas across the advocacy community. This forum aims to foster patient-focused collaboration, share best practices and provide resources aimed at improving patient care.
Astellas is working with Cytokinetics to develop CK-2127107, a muscle activator for SMA. The drug is currently being tested in a Phase 2 clinical trial.